ResearcherKorea Research Institute of Bioscience and BiotechnologyNo recent work listed

Young Il Yeom

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4279-805X; OpenAlex author ID A5066139777. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2015: 1 paper

Papers 1

Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells. Last author DOI 10.1016/j.yexcr.2015.05.017 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Dong Joon Kim · 1 shared paper, 2015 · strength 0.04
- Paper Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells. DOI 10.1016/j.yexcr.2015.05.017 ↗
Mi‐Ju Kim · 1 shared paper, 2015 · strength 0.04
- Paper Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells. DOI 10.1016/j.yexcr.2015.05.017 ↗
Seung‐Mo Hong · 1 shared paper, 2015 · strength 0.04
- Paper Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells. DOI 10.1016/j.yexcr.2015.05.017 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.